Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>Jefferies Cuts ALI HEALTH (00241.HK) TP to HKD5.3, Reiterates Buy
Recommend 21 Positive 27 Negative 14 |
||||
|
||||
|
ALI HEALTH (00241.HK) launched the "Hydrion" app, positioning it as an early AI pioneer targeting doctors, in collaboration with The BMJ to provide evidence-based clinical decision support, Jefferies said in its report. Initial product testing shows strong usability, a low hallucination rate and robust clinical reasoning. Management expects to invest RMB200-300 million annually in AI R&D during FY2027-29, targeting 2 million MAUs within three years and aiming for "Hydrion" to achieve breakeven in 2029. As a leading B2C participant, ALI HEALTH's internet hospital workflow has been officially authorized and is largely unaffected by recent news regarding tightened GLP-1 prescription restrictions in Jiangxi and Shanghai. The broker lowered its TP on ALI HEALTH from HKD6 to HKD5.3 to reflect uncertainties such as commercialization pace, but maintained its Buy rating. Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
